Esperion Therapeutics Inc (NAS:ESPR)
$ 2.16 -0.13 (-5.68%) Market Cap: 409.24 Mil Enterprise Value: 476.24 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 55/100

Esperion Therapeutics Inc at UBS Global Healthcare Conference Transcript

May 20, 2019 / 01:30PM GMT
Carter Lewis Gould
UBS Investment Bank, Research Division - Large Cap Biotech Analyst

Okay. Great. Good morning. My name is Carter Gould. I am a senior biotech analyst here at UBS. Welcome to day 1 of the Global Healthcare Conference. I'm pleased to welcome Esperion to the stage. Presenting for the company will be CEO, Tim Mayleben. Just a little bit of perspective. A year ago, almost, we were getting one of the first set of Phase III data from Esperion, and since that time they've made pretty remarkable progress, advancing towards approval, all filed with the FDA now, and I'll let Tim to take it from there, he's going to make some opening comments and then we'll sit down for Q&A.

Timothy M. Mayleben
Esperion Therapeutics, Inc. - President, CEO & Director

Perfect. Good morning, everyone. Thanks, Carter, and thanks to UBS for the opportunity to be here with you this morning. As Carter said, it's been an eventful and very productive year. I've got 6 or 8 slides that I'm going to run through with you. And then as Carter said, we're going to move to Q&amp

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot